# Gyre Therapeutics (GYRE) — News

GYRE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gyre/news

## Recent headlines

- [Gyre Therapeutics affirms FY2026 revenue guidance of $100.50 mln-$111 mln](https://www.ainvest.com/news/gyre-therapeutics-affirms-fy2026-revenue-guidance-100-50-mln-111-mln-2608) — AInvest Wire, Aug 7, 2026
  Gyre Therapeutics (NASDAQ: GYRE) has reaffirmed its full-year 2026 revenue guidance of $100.50 million to $111.00 million, as outlined in its recent first-quarter 2026 earnings report . The company reported Q1 2026 revenue of $22.5 million, which marked a modest increase compared to the same period…
- [Gyre Therapeutics appoints three new members to its board of directors](https://www.ainvest.com/news/gyre-therapeutics-appoints-members-board-directors-2607) — AInvest Wire, Jul 16, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).